Analysis of therapy-induced changes in gene expression, tumorigenicity and invasiveness of circulating, epithelial tumor cells (CETCs)

Recruiting

• Conditions: C18; C19; C20; Malignant neoplasm of colon; Malignant neoplasm of rectosigmoid junction; Malignant neoplasm of rectum

• Registration Number: DRKS00015530
• Lead Sponsor: niversität Bayreuth

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

histologically verified, invasive colorectal carcinoma (C18, C19, C20); initial diagnosis; stage I-IV; medical treatment in the Hospital Bayreuth, only; minimum 2 blood withdrawals (before and after a guideline-conform radio/chemotherapy or surgery)

Exclusion Criteria

lack of consent; unrelated, preceding malignancies < 10 years before the diagnosis of the colorectal carcinoma; pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CETC numbers in the course of guideline-conform treatment of colorectal carcinoma (stage I-IV) (Maintrac protocol); <br>gene expression, tumorigenicity and invasivity of CETCs (and if applicable primary tumor cells) in the course of guideline-conform therapy of colorectal carcinoma (single cell picking, PCR, pysical and biochemical assays); overall survival (follow up after 3 and 5 years via cancer registry) and progression-free survival (follow up after 3 and 5 years via cancer registry)

Secondary Outcome Measures

Name	Time	Method
Comparison of gene expression, tumorigenic and invasive properties of CETCs with those of primary tumor cells (single cell picking, PCR, physical and biochemical assays)